Pliant Therapeutics, Inc. (PLRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Pliant Therapeutics, Inc. (PLRX) closed at USD 0.97 on 2026-10-15, a change of -44.1 % over the past year, with a market capitalization of USD 55.72M.

Pliant Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Pliant Therapeutics, Inc. key figures

Previous close

USD 0.97 (2026-10-15)

1-year change

-44.1 %

Market cap

USD 55.72M

Enterprise value

USD -73.63M

P/E ratio (trailing)

-0.60

P/E ratio (forward)

-0.70

EPS (trailing)

-1.50

EPS (forward)

-1.28

PEG ratio

n/a

Price to book

0.38

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.75

Employees

49

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Pliant Therapeutics, Inc. and compare it with other stocks.